MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Post-Mkt 02-26 18:26:52 EST

2.18

-0.14

-6.03%

盘后2.20

+0.02+0.95%

17:59 EST

High2.34	Low2.12	Vol538.79K
Open2.29	D1 Closing2.32	Amplitude9.48%
Mkt Cap80.73M	Tradable Cap61.78M	Total Shares37.03M
T/O1.19M	T/O Rate1.90%	Tradable Shares28.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":2.18,"timestamp":1772139600000,"preClose":2.32,"halted":0,"volume":538785,"hourTrading":{"tag":"盘后","latestPrice":2.2007,"preClose":2.18,"latestTime":"17:59 EST","volume":174,"amount":380.7740136,"timestamp":1772146755054,"change":0.0207,"changeRate":0.009495,"amplitude":0.018349},"delay":0,"changeRate":-0.06034482758620676,"floatShares":28340000,"shares":37032307,"eps":-0.768287,"marketStatus":"Post-Mkt","change":-0.14,"latestTime":"02-26 18:26:52 EST","open":2.29,"high":2.34,"low":2.12,"amount":1185249.199446,"amplitude":0.094828,"askPrice":2.33,"askSize":2,"bidPrice":2.16,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.768287,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772154000000},"marketStatusCode":4,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":2.32,"preHourTrading":{"tag":"盘前","latestPrice":2.32,"preClose":2.32,"latestTime":"09:28 EST","volume":4946,"amount":11375.713445,"timestamp":1772116097641,"change":0,"changeRate":0,"amplitude":0.021466},"postHourTrading":{"tag":"盘后","latestPrice":2.2007,"preClose":2.18,"latestTime":"17:59 EST","volume":174,"amount":380.7740136,"timestamp":1772146755054,"change":0.0207,"changeRate":0.009495,"amplitude":0.018349},"volumeRatio":0.724163},"requestUrl":"/m/hq/s/MAIA/tweets","defaultTab":"tweets","newsList":[{"id":"2613871781","title":"MAIA Biotechnology published a 2026 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871781?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:50","pubTimestamp":1771941043,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-published-a-2026-letter-to-shareholders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-published-a-2026-letter-to-shareholders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2613271292","title":"Maia Biotechnology Publishes February 2026 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2613271292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613271292?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:46","pubTimestamp":1771940769,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. published a 2026 shareholder letter highlighting updates on ateganosine  clinical development in non-small cell lung cancer. The letter cites interim Phase 2 THIO-101 results of 88% disease control rate, 38% overall response rate, and 17.8 months median overall survival, and notes FDA Fast Track designation granted in July 2025. The letter also states Phase 3 THIO-104 is underway with up to 300 patients planned and indicates Phase 2 THIO-101 Part C is nearing completion with a potential accelerated approval pathway. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief on Febru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5TdhBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2613871297","title":"Maia Biotechnology Announces Availability of 2026 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2613871297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613871297?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:45","pubTimestamp":1771940714,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Announces Availability of 2026 Shareholder Letter               Maia Biotechnology Inc. announced that its 2026 Letter to Shareholders is now available at ir.maiabiotech.com.       ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7Cl5F7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","SG9999014039.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2613971013","title":"MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2613971013","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613971013?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:45","pubTimestamp":1771940700,"startTime":"0","endTime":"0","summary":"Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243622/0/en/MAIA-Biotechnology-s-Phase-3-Momentum-Demonstrates-Potential-Breakthrough-Anticancer-Opportunity-in-50-Billion-Immunotherapy-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","LU0210528500.USD","BK4107","BK4585","L","LU0053666078.USD","LU2487616109.SGD","BK4588","BK4139","MAIA"],"gpt_icon":0},{"id":"2605142385","title":"MAIA Biotechnology outlines 2026 goals for ateganosine program","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142385?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:04","pubTimestamp":1768946697,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an update. On January 20, 2026, MAIA Biotechnology reported on its 2025 progress and set out key cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-outlines-2026-goals-for-ateganosine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-outlines-2026-goals-for-ateganosine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2604485112","title":"MAIA Biotechnology highlights milestones, catalysts for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2604485112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604485112?lang=en_us&edition=fundamental","pubTime":"2026-01-20 23:25","pubTimestamp":1768922723,"startTime":"0","endTime":"0","summary":"Targeted 2026 Milestones: Initial measures of efficacy from Phase 3 study. Interim disease control rates, overall response rates and progression fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-highlights-milestones-catalysts-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-highlights-milestones-catalysts-for-fy26-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2604114054","title":"Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine","url":"https://stock-news.laohu8.com/highlight/detail?id=2604114054","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604114054?lang=en_us&edition=fundamental","pubTime":"2026-01-20 23:15","pubTimestamp":1768922110,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced a business update highlighting key achievements in 2025 and outlining targeted milestones for 2026. The company reported strong clinical execution in 2025, delivering efficacy data for ateganosine, its telomere-targeting anticancer agent, sequenced with a checkpoint inhibitor in third-line non-small cell lung cancer . Results showed disease control, response rates, and survival data exceeding standard of care benchmarks. Ateganosine received FDA Fast Track designation in 2025, supporting concurrent Phase 2 and Phase 3 trials and positioning the drug for potential Accelerated Approval and Priority Review. Maia Biotechnology also established combination partnerships with Roche for atezolizumab and BeOne Medicines for tislelizumab. The company raised approximately $17.6 million in capital during 2025, with board members participating in nearly all transactions. As of December 31, 2025, directors and officers collectively hold more than 5 million shares, r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL2pNhYc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","MAIA","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2603850656","title":"MAIA Biotechnology Highlights Strategy in New Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603850656","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603850656?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:48","pubTimestamp":1768344530,"startTime":"0","endTime":"0","summary":"An update from MAIA Biotechnology, Inc. ( ($MAIA) ) is now available. On January 13, 2026, MAIA Biotechnology, Inc. filed and published a set of in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-highlights-strategy-in-new-investor-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2602543866","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543866","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543866?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:44","pubTimestamp":1768225499,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL79tlWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2593147221","title":"MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings","url":"https://stock-news.laohu8.com/highlight/detail?id=2593147221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593147221?lang=en_us&edition=fundamental","pubTime":"2025-12-24 21:01","pubTimestamp":1766581260,"startTime":"0","endTime":"0","summary":"Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.  24, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/24/3210313/0/en/MAIA-Biotechnology-Board-Members-Continue-to-Participate-in-Private-Placement-Financings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4107","LU0053666078.USD","L","LU0210528500.USD","MAIA","BK4585","LU2487616109.SGD","BK4588"],"gpt_icon":0},{"id":"2593186524","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593186524","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593186524?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:19","pubTimestamp":1766495973,"startTime":"0","endTime":"0","summary":"Stan Smith, Director, reported an acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL5Dk2VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2593418394","title":"Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418394","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593418394?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:15","pubTimestamp":1766495720,"startTime":"0","endTime":"0","summary":"Ngar Yee Louie, a Director at Maia Biotechnology Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL7wD6gS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2592930351","title":"MAIA Biotechnology Announces $1.51 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592930351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592930351?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:15","pubTimestamp":1765919700,"startTime":"0","endTime":"0","summary":"CHICAGO, IL, Dec.  16, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206621/0/en/MAIA-Biotechnology-Announces-1-51-Million-Private-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2590154348","title":"MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154348","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154348?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:00","pubTimestamp":1765476000,"startTime":"0","endTime":"0","summary":"CHICAGO, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), ap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204217/0/en/MAIA-s-Ateganosine-Surges-Ahead-with-Breakthrough-Momentum-as-Pivotal-Phase-3-Trial-Initiates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2590511840","title":"Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511840?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3HFJZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2590516848","title":"Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516848","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516848?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458041,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced that CEO Dr. Vlad Vitoc and other board members have acquired approximately 182,445 shares of the company in open-market purchases between November 21 and 28, 2025. This latest round of insider buying reflects continued confidence in the company's strategy and the potential of its telomere-targeting cancer therapy, ateganosine. Directors and Officers now collectively hold 4,480,120 shares, representing 12.95% of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2Lz6Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MAIA","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4139","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","SG9999014021.USD","BK4112","BK4588"],"gpt_icon":0},{"id":"2590324095","title":"Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590324095","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590324095?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:00","pubTimestamp":1765393212,"startTime":"0","endTime":"0","summary":"Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer  who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLc6fPHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","MAIA","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2590240483","title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590240483","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590240483?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:51","pubTimestamp":1765317118,"startTime":"0","endTime":"0","summary":"Stan Smith, Director of Maia Biotechnology Inc., reported the acquisition of common shares of Maia Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL6r5Jkb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"gpt_icon":0},{"id":"2588730867","title":"BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588730867","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588730867?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:18","pubTimestamp":1764598691,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And DirectorsDec 1 (Reuters) - Maia Biotechnology Inc MAIA.A:MAIA BIOTECHNOLOGY ANNOUNCES OPEN MARKET PURCHASES BY CEO AND DIRECTORSMAIA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"gpt_icon":0},{"id":"2588773741","title":"Maia Biotechnology Announces Open Market Purchases by CEO and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588773741","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588773741?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:17","pubTimestamp":1764598620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9VSMFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maiabiotech.com","stockEarnings":[{"period":"1week","weight":0.1154},{"period":"1month","weight":-0.1145},{"period":"3month","weight":1.1887},{"period":"6month","weight":0.5065},{"period":"1year","weight":0.3333},{"period":"ytd","weight":0.5163}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.054596},{"month":3,"riseRate":0.333333,"avgChangeRate":0.091126},{"month":4,"riseRate":0.666667,"avgChangeRate":0.190738},{"month":5,"riseRate":0.666667,"avgChangeRate":0.134126},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.131471},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058081},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}